The New England Journal of Medicine

Perspective
Who Should Receive Myeloablative Therapy for Lymphoma?
T. A. Lister - 25 Mar, 2004

NEJM article This article requires a subscription.

Sign In

Login via Athens or your institution

Already a print subscriber? Activate your online access

Not a Subscriber?

Get full access to NEJM Online now with a FREE TRIAL!

Free Trial

Or, purchase access to this
article for $10


Advertisement
Advertisement

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.